Dr Anggraini Alam, Sp.A(K) Head of the Coordination Work Unit for Tropical Diseases & Infections – the Indonesian Pediatrician Association (IDAI) hopes that there will be more dengue vaccination options with a wider reach for the community.
“We hope that over time there will be more innovations in dengue vaccine options that are available, which can be given to people with a wider age range, with fewer doses and at an affordable cost.” said Anggraini, as quoted BetweenWednesday (20/7/2022).
He explained that currently there is one dengue vaccine product available in Indonesia and has received a permit from the Food and Drug Supervisory Agency (BPOM). The vaccine is available for children aged 9-16 years who have been infected with dengue in three doses. Dengue vaccines are readily available in hospitals and pediatricians for outpatient treatment.
Anggraini also emphasized that prevention is more important than healing. Therefore, the dengue vaccine is a new innovation that is needed in an effort to prevent dengue disease in Indonesia.
Dengue is a sudden high fever and is caused by the dengue virus and is transmitted by the Aedes aegypti mosquito. In addition to high fever, signs include headache, muscle and joint pain, pain behind the eyes, skin rash, loss of appetite, bleeding and nausea and vomiting.
Bleeding in dengue can include nosebleeds, bleeding gums, red skin spots on the face, neck, chest or upper back, black stools or excessive menstrual blood.
The critical phase of dengue disease occurs when the fever begins to fall, where there is a potential for complications in dengue between the third and seventh day. In the critical phase there are potential complications such as shock due to massive plasma leakage, brain hemorrhage, metabolic abnormalities, fulminant liver failure to prolonged shock that leads to death. (ant/des/ipg)
–
